DARVON-N W/ ASA
LOE Approachingaspirin; propoxyphene napsylate
NDAORALTABLET
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON-N W/ ASA is an oral tablet combining propoxyphene napsylate (an opioid analgesic) with aspirin for pain relief. The combination targets mild-to-moderate pain by leveraging both opioid and NSAID mechanisms. This fixed-dose formulation was a standard analgesic offering from the 1970s onward.
LOE Approaching
With LOE approaching and minimal commercial investment signals, brand teams face workforce consolidation and transition planning to post-LOE support models.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, career prospects on DARVON-N W/ ASA are severely limited. Working on this legacy product offers minimal skill-building and high risk of team downsizing, making it an unattractive career destination for growth-focused professionals.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.